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Figure 1. Anti-inﬂammatory cytokine concentrations.* signiﬁcantly < APS
Device System (p<0.05, t-test).
Figure 2. Anabolic growth factor concentrations.* signiﬁcantly < APS
Device System (p< 0.05, t-test).
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S484cartilage degradation and conﬁrms a link between a native biological
pathway and pharmacology which translates to human tissues and
non-human primate models, subsequently pointing to a speciﬁc OA
patient population to target. However, our results suggest selective and
potent ADAMTS-5 engagement/inhibition with GSK2394002, while
demonstrating desired effects on cartilage-related endpoints, results in
modulation of CV functions that pose considerable challenges for clin-
ical development.
884
COMPARISON OF THE CELLULAR AND CYTOKINE CONCENTRATIONS
IN THE OUTPUT OF THE AUTOLOGOUS PROTEIN SOLUTION,
ORTHOKINE, AND ONOCCOMED 2 DEVICE SYSTEMS
W. King, J. Woodell-May. Biomet, Warsaw, IN, USA
Purpose: The purpose of this study was to characterize the cellular and
cytokine concentrations in the outputs of the Autologous Protein Sol-
ution (APS), Orthokine, and Onoccomed 2 Device Systems. Anti-
inﬂammatory cytokines and anabolic growth factors were analyzed due
to their potential role in inhibiting damaging inﬂammation in osteo-
arthritis (OA) and inducing disease-modifying cartilage repair.
Methods: Blood from 6 human donors (WIRB Study # 1115097) was
drawn and allocated so that blood from each donor was used for 1)
whole blood analysis, 2) processing with the APS Device System (Bio-
met, Warsaw, IN, USA), 3) Orthokine Device System (Orthogen Lab
Services, Dusseldorf, Germany), and the Onoccomed 2 Device System
(Plasmaconcept AG, Bonn, Germany). Each device systemwas processed
according to the manufacturer’s instructions. Cellular content was
analyzed using a Cell Dyn 3700 hematology analyzer (Abbott Labo-
ratories, Chicago, IL, USA). Cytokine content was measured using
enzyme-linked immunosorbent assays (R&D Systems, Minneapolis,
MN, USA).
Results: The APS Device System produced a solution with greater
concentrations of white blood cells (WBC) and platelets (PLT) than
whole blood, the output of the Orthokine Device System, and the
Onoccomed 2 Device System (p < 0.05, t-test). The output of the APS
Device System contained signiﬁcantly decreased red blood cell (RBC)
concentrations than whole blood, but greater than the RBC concen-
trations in the conditioned serums produced by the Orthokine and
Onoccomed 2 Device Systems (p < 0.05, t-test) (Table 1).
The APS Device System produced solutions with signiﬁcantly greater
concentrations of anti-inﬂammatory cytokines than the Orthokine and
Onoccomed 2 device systems (Figure 1). For example, the concentration
of interleukin-1 receptor antagonist (IL-1ra) in the output of the APS
device system was 54,922.1  32,750.7 (pg/ml), whereas the output of
the Orthokine device systemwas 1,618.0 674.7 (pg/ml) and the output
of the Onoccomed 2 device system was 277.1  338.2 (pg/ml). The
concentration of IL-1ra in the outputs of the Orthokine and Onoccomed
2 device systems were signiﬁcantly less than the IL-1ra concentration in
whole blood (5664.5  2,317.6 pg/ml) (p < 0.05). The output of the APS
device system also contained signiﬁcantly greater concentrations of
soluble interleukin-1 receptor antagonist type II (sIL-1RII), soluble
tumor necrosis factor type I (sTNF-RI), and sTNFR-II (p < 0.05, t-test)
(Figure 1).
The APS Device System produced solutions with similar or signiﬁcantly
greater concentrations of anabolic growth factors compared to the
other device systems. For example, the APS Device System produced a
solution that contained 13,575.9  5,959.2 (pg/ml) platelet-derived
growth factor-BB (PDGF-BB). The Onoccomed 2 and Orthokine device
systems had outputs containing 2,302.3  1,022.6 and 2,765.5  1,101.2
(pg/ml) PDGF-BB, respectively (p < 0.05, t-test). The APS Device System
also produced solutions with signiﬁcantly greater concentrations of
PDGF-AB, transforming growth factor-b (TGF-b), and epidermal growth
factor (EGF) compared to the Onoccomed 2 Device System (p < 0.05, t-Table 1
Concentration of white blood cells (WBC) (k/ml), Platelets (k/ml), and red blood cells
(RBC) (M/ml)
WBC (k/ml) PLT (k/ml) RBC (M/ml)
Whole blood 5.4  1.8 175.1  69.5 5.5  1.1
APS 46.5  19.9 1184.4  556.4 1.4  1.5
Orthokine 0.0  0.0 13.5  5.5 0.0  0.0
Onoccomed 2 0.0  0.0 11.4  1.7 0.0  0.0test). There were no signiﬁcant differences in the concentrations of EGF,
insulin-like growth factor-1 (IGF-1), and TGF-b in the outputs of the APS
and Orthokine device systems. However, the APS Device System pro-
duced solutions with signiﬁcantly greater concentrations of PDGF-AB
and PDGF-BB than the Orthokine Device System (p < 0.05, t-test).
Conclusions: The APS device system produced solutions with sig-
niﬁcantly greater concentrations of anti-inﬂammatory cytokines and
similar or greater concentrations of anabolic growth factors than the
Orthokine or Onoccomed 2 Device Systems. Signiﬁcantly, the average
IL-1ra concentration in the output of the APS Device system was 34X
that of the Orthokine Device System and 198X that of the Onoccomed 2
Device System from the same donors. The cytokine proﬁle of APS can be
attributed to its increased concentrations of WBC and platelets com-
pared to the acellular conditioned serums.
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DEVELOPMENT OF GROWTH FACTOR TETHERED HYALURONAN
MICROSPHERES FOR IN SITU CHONDROGENIC DIFFERENTIATION
OF HUMAN MESENCHYMAL STEM CELLS
S. Ansboro y, J.S. Hayes y, V. Barron y, S. Browne z, L. Howard y,
U. Greiser z, P. Lalor x, F. Barry y, A. Pandit z, M. Murphy y. y The
Regenerative Med. Inst. (REMEDI), Natl. Univ. of Ireland, Galway,
Galway, Ireland; zNetwork of Excellence for Functional Biomaterials
(NFB), Natl. Univ. of Ireland, Galway, Galway, Ireland; x The Ctr. for
Microscopy and Imaging (CMI), Natl. Univ. of Ireland, Galway, Galway,
Ireland
Figure 1: In vitro chondrogenesis of hMSCs. Results indicate a signiﬁcant
increase in GAG deposition and collagen type II expression with the
addition of TGFb3 HA microspheres. *p ¼ 0.05
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S485Purpose: Transforming growth factor beta (TGF-b) is an important
regulator in determining cell fate of human mesenchymal stem cells
(hMSCs), speciﬁcally down the chondrogenic lineage. Yet control of this
differentiation within a complex in vivo milieu remains a challenge. A
localized therapy such as an intra-articular injection of a system for
controlled release of TGF-b3 would represent a readily translatable
approach for in situ differentiation and remove the need for continuous
supplementation of growth factors. Hyaluronan (HA) is an essential
component of cartilage extracellular matrix (ECM) and serves as a
support for cell adhesion, spreading and subsequently, cell growth.
Thus, our aim was to fabricate chondromimetic HA microspheres and
test these as extracellular growth factor targeting depots for initiation of
in vitro and ex vivo chondrogenesis of hMSCs.
Methods:HAmicrospheres were fabricated using an electrostatic layer-
by-layer strategy and characterized by scanning electron microscopy.
hMSCs isolated from the iliac crest of healthy donors were obtained
with approval from the National University of Ireland Galway and
associated University College Hospital ethics committees and cultured
in a-MEM containing 10% FBS, 100U/ml penicillin and 100mg/ml
streptomycin. The effects of microspheres on cell number andmetabolic
activity were determined using the PicoGreen dsDNA and
alamarBlue assays. Confocal microscopy, ﬂow cytometry and trans-
mission electronmicroscopy were utilized to investigate co-localization
of HA microspheres with hMSCs to ensure they were not taken up by
cells. TGF-b3 was loaded onto HA microspheres via passive diffusion
(400ng/mg), incubated with hMSCs and cultured for 21 d in incomplete
chondrogenic medium (ICM) or complete chondrogenic medium (CCM)
(þ10ng/ml TGF-b3 every 2 d) to assess in vitro chondrogenesis. Gly-
cosaminoglycan (GAG) measurement (DMMB assay), chondrogenic
transcripts (qRT-PCR) and immunohistochemical staining (IHC) were
used to validate successful chondrogenesis. For ex vivo culture experi-
ments, fresh human articular cartilage samples were obtained under
institutionally approved protocols from Merlin Park Hospital, Galway
from donors who had undergone knee replacement surgery. Cartilage
explants were allowed to equilibrate at 37C for 48 h in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) þ 10% fetal bovine serum and sub-
sequently equilibrated for 24 h in ICM in an agarose well prior to
switching to ICM or CCM media and treated with or without TGF-b3
loaded microspheres for 21 d culture. Experiments were performed for
3 donors with each experiment containing a minimum of three bio-
logical replicates. Statistical signiﬁcance was assessed using one-way orFigure 2: Ex-vivo culture of human articular cartilage explants for 21 d in
ICM with human mesenchymal stems with or without TGFb3 loaded HA
microspheres.two-way ANOVA followed by Tukey or Bonferroni post hoc analysis and
denoted signiﬁcant for p ¼ 0.05.
Results: HA microspheres retained their spherical morphology with
uniform size distribution. Cellular compatibility studies indicated no
adverse effects of 10mm HA microspheres. Following TGF-b3 loading of
microspheres, incubation with hMSCs for 21 d in vitro pellet culture
revealed enhanced accumulation of GAGs (Fig. 1A) and positive IHC of
collagen type II in hMSCs incubated with growth factor loaded HA
microspheres when compared to control cells. Additionally, qRT-PCR
analysis from 14 d pellets revealed enhanced expression of aggrecan
and collagen type II (Fig. 1B). 21 d explant culture indicated localization
of TGF-b3 HA microspheres within ﬁbrillations of osteoarthritic carti-
lage with implanted hMSCs and local chondrocytes showing increased
GAG deposition compared to hMSCs alone (Fig. 2, arrow indicative of
increased GAG staining in surrounding cells).
Conclusion: Injectable biomaterials hold great promise for orthopaedic
applications, in particular for repair of articular cartilage. Preliminary in
vitro/ex-vivo evidence presented here supports the use of TGF-b3-
loaded HA microspheres for in situ differentiation of hMSCs.
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PRODUCING ARTIFICIAL CHONDRONS FOR IMPROVED CARTILAGE
REPAIR
T. Kamperman, J.C. Leijten, S.J. Henke, M. Karperien. Univ. of Twente,
Enschede, Netherlands
Purpose: Articular cartilage has a limited capacity for self-repair and
untreated damage often leads to the development of osteoarthritis and
eventually joint failure. Currently, autologous chondrocyte implanta-
tion is the most successful method for repairing focal cartilage defects.
This therapy involves the isolation of chondrocytes from articular car-
tilage by enzymatic degradation. This not only strips the cells from their
extra cellular matrix, but also from their highly specialized micro-
environments, called chondrons. This initiates dedifferentiation, i.e. the
isolated chondrocytes progressively lose their chondrogenic phenotype,
and thus reduces the clinical success of the therapy. We aim to develop
a strategy to encapsulate expanded single chondrocytes in artiﬁcial
chondrons. When successful, this approach represents a cost-effective
method to prevent further dedifferentiation, while simultaneously
allows for optimal stimulation of the encapsulated chondrocytes. Here,
we present a microﬂuidic device able to encapsulate single chon-
drocytes in chondron-sized (<50 mm) microgels in a custom designable
artiﬁcial matrix using an efﬁcient and cell-friendly manner.
Methods: The master mould for the optimized microﬂuidic droplet
generator was made by micropatterning w25 mm thick SU8-50
(MicroChem) on a silicon wafer using standard photolithography
techniques. PDMS (Sylgard 184, Dow Corning) was thermally cured on
the master and bonded to glass after plasma treatment. Aquapel (Vul-
cavite) was introduced in the chip before usage to ensure hydrophobic
channels walls. We compared various combinations of oils, surfactants,
photoinitiators and UV dosages, as these are of paramount importance
to obtain chondron-sized microgels. Chondron-sized droplets were
produced by emulsifying a chondrocyte-laden hydrogel precursor sol-
ution of 10% (w/v) polyethylene glycol diacrylate (PEGDA, Laysan Bio,
Inc.) and 0.1% (w/v) photoinitiator (Irgacure 2959, Ciba Specialty
Chemicals) in hexadecane (Sigma) with 1% Span80 (Sigma). Sub-
sequently, the microgels were formed in an on-chip delay channel by
curing the emulsion with 365nm UV-light (Hamamatsu LC8).
Results: Chondrocytes were encapsulated in PEGDA microgels using
droplet microﬂuidics at a rate of typically 20,000 cells per minute. The
number of encapsulated cells followed a Poisson-distribution that was
dependent on the cell concentration. We aimed to minimize the
microgels’ dimensions by comparing different combinations of oils,
surfactants and UV dosages. Fluorinated oils in combination with
PEGylated ﬂuorosurfactants resulted in the most stable emulsions and
thus allowed for the lowest photoinitiator concentration and UV dose
for cell-laden microgel production. However, the use of ﬂuorinated oils
resulted in relatively large gels, which is a consequence of their low
viscosity compared to the hydrogel precursor solution. In contrast, the
use of a more viscous hydrocarbon oil with Span80 surfactant resulted
in smaller, chondron-sized microgels. However, emulsions with this oil/
surfactant combination were less stable off-chip. Solid on-chip cross-
linking was accomplished by using an extended delay channel which
enabled prolonged UV radiation without compromising the production
rate. Finally, by varying the ﬂow rates of the continuous and dispersed
